Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, toda...

And today we get proof-of-concept #MC4R receptor agonist #obesity data from #PalatinTechnologies in a 8-week study showing enhanced weight loss when given on top of #tirzepatide:

#$PTN sees opportunity in hypothalamic obesity.

finance.yahoo.com/news/palatin...